Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients. GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is a targeted therapy used within the chronic myeloid leukemia treatment pathway. - Chronic Myeloid Leukemia (CML): improves hematologic and cytogenetic response and reduces disease progression. - Accelerated‑phase CML: helps achieve hematologic remission and stabilises disease. - Blast‑phase CML: provides disease control when other options are limited.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring intermittently. - Rash: skin irritation or erythema. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm disturbance requiring ECG monitoring. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe liver injury: marked elevation of liver enzymes or hepatitis.

Patients should be monitored for specific safety concerns before and during therapy. - Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT‑interval risk. - Liver function: assess hepatic enzymes prior to initiation and regularly thereafter. - Hematologic surveillance: perform complete blood counts to detect neutropenia or thrombocytopenia. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that may increase nilotinib exposure. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib may interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise plasma levels. - QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmia. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may modestly increase exposure. - St. John’s wort: enzyme induction can lower drug concentrations. - Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring.